Background: Asthma and Non-Asthmatic Eosinophilic Bronchitis(NAEB) are commonly treated with inhaled corticosteroids(ICS) and bronchodilators. It is unclear if the change in cough patient reported outcomes(PRO) is associated with a corresponding reduction in type 2 biomarkers(T2B).

Objective: Evaluate the relationship between improvements in cough PROs and improvements in T2B in CC patients treated with ICS/LABA.

Methods: A prospective observational single center cohort study. Patients were treated with ICS/LABA based on results from methacholine challenge and T2B including blood eosinophils, Fractional Exhaled Nitric Oxide(FeNO) and % sputum eosinophils. Cough PROs included measuring Leicester Cough Questionnaire(LCQ), cough severity visual analogue scale(VAS).

Results: 69 patients with CC (49females;mean age,55.7±14.5yrs) were recruited. 28 patients were treated with ICS/LABA. Of these, 9 patients were responders(32%) and reported LCQ and VAS improvements above the MID(VAS change -45.0mm and LCQ change 8.2)(Fig 1). No significant relationship was observed between changes in T2B and subjective cough outcomes.

Reduction in cough in responders was associated with a numerical reduction of 18.55ppb in FeNO and sputum eosinophils by 1.6%.

Conclusions: Treatment with ICS/LABA resulted in improvement in cough PROs only in 32% of patients with CC. Elevated T2B seem to poorly predict treatment responses in CC patients.